Currently, there are eleven million cataract patients in China, and this rate increases by 400,000 cases annually \[statistics reported by the Ministry of Health of the People's Republic of China (<http://www.nhfpc.gov.cn>)\]. Last year, there were 1.9 million cataract surgeries performed[@b1]. Unfortunately, due to both social and economic factors, there are still large gaps in the levels of medical care provided among the different districts and hospitals in China. In a previous study published in the British Journal of Ophthalmology on July 24, 2013, we focused on top eye centers (cataract surgery volume ≥150 cases per month), which represent the most advanced medical care environment in China. We investigated the occurrence rate of acute-onset endophthalmitis after 201,757 cataract surgeries in eight centers between 2006 and 2011 (0.033%), which was close to that reported in developed countries[@b2]. Obviously, that study could not determine the overall status of the postoperative endophthalmitis incidence and treatment throughout the whole country. In order to reveal the status of most hospitals in China, the Board of the Chinese Cataract Society sampled 30 hospitals with small and medium-scale departments of ophthalmology, whose cataract surgery volume ranged from 10 to 100 cases per month. This was to investigate the occurrence rate of acute-onset endophthalmitis after cataract surgery, and assess the treatment standards. In addition, the study focused on effective infection prophylaxes and the associated risk factors.

Results
=======

From January 2011 to December 2013, 59,392 cataract surgeries were performed in these 30 departments. The average cataract surgery volume was 659.9 cases per year (range 175--1,199), and the overall follow-up rate of the patients at 2 months was 77.8%. Considering that the acute-onset postoperative endophthalmitis was diagnosed within 6 weeks, those patients without 2-month follow-up records were excluded. In total, 46,185 cataract surgeries were included in the analysis: 40,848 phacoemulsifications and 5,337 ECCEs. Fifty-two eyes of 52 patients developed acute-onset endophthalmitis following cataract surgery in these 46,185 operations, which was an occurrence rate of 0.11% (95% CI 0.08 to 0.14), and there were no significant differences among the three separate years. The 30 departments achieved different occurrence rates for postoperative endophthalmitis, ranging from 0.03% to 0.60% ([Table 1](#t1){ref-type="table"}).

Regarding the infection prophylaxes, 43.3% of the centers (13/30) trimmed the patients' lashes, and 56.7% (17/30) irrigated with 0.5% PVP-I solution for the conjunctiva preparation. Antibiotics were added to the irrigation solution (16 mg/l tobramycin or 8 mg/l gentamicin) by 10.0% of the centers (3/30), while 86.7% of the centers (26/30) used tobramycin (subconjunctival injection or ointment) upon completing the surgery.

The mean age of these 52 patients (20 males, 32 females) was 68.3 years old (range 28--92). Among these 52 cases, five underwent ECCE and 47 underwent phacoemulsification. Seventeen of the patients were from hospitals whose cataract surgery volume was less than 500 cases per year. The occurrence of intraoperative posterior capsule rupture with vitreous loss was noted in three of the 52 patients. Twenty-five patients were treated without 0.5% PVP-I irrigation for the conjunctiva preparation, and the median interval between the surgery and diagnosis was 6.18 days (range 1--20). After removing two cases that lacked data regarding the patient's presenting visual acuity, 92% of the cases (46/50) had visual acuities worse than 20/70 at presentation, while 74% (37/50) were worse than 20/1,000. Based upon the sampling results of the aqueous humor or vitreous body, the rate of culture positivity was 44.2% (23/52). Of the 20 culture-positive cases, *Staphylococcus epidermidis* (43.5%) was the most commonly isolated organism ([Table 2](#t2){ref-type="table"}). For the therapy, 59.6% of the cases (31/52) were treated with the proper antibiotics (according to the culture results, or with the use of broad-spectrum antibiotics), while 38.5% of the cases (20/52) received pars plana vitrectomy treatment. In addition, 51.9% of the cases (27/52) reported a final corrected distance visual acuity (CDVA) of 20/70 or better, but only 32.7% of these had a visual acuity of better than 20/40.

The multivariate analysis showed that an intraoperative posterior capsule rupture (PCR) with vitreous loss (OR = 4.40; 95% CI 1.34--14.14; p = 0.034), a small cataract surgery volume (less than 500 cases per year) (OR = 2.21; 95% CI 1.24--3.94; p = 0.006), and the absence of 0.5% PVP-I solution irrigation (OR = 1.73; 95% CI 1.01--2.98; p = 0.046) were independent risk factors for the development of postoperative endophthalmitis. To identify the relationship between PCR and postoperative endophthalmitis, we first analyzed this complication as a factor, but found there was no association between them (p = 0.614). Then, we divided this complication into two case types: PCR with vitreous loss and PCR without vitreous loss. We found that only the PCR with vitreous loss was associated with endophthalmitis (p = 0.034), while the PCR without vitreous loss was not a risk factor (p = 0.55). The age, gender, systemic disease, place of surgery, type of surgery, antibiotic irrigation, hospital geographic pattern, and general level of the location's city were unrelated to the risk of endophthalmitis ([Table 3](#t3){ref-type="table"}).

Finally, we constructed a logistic regression model of the visual outcome (final BCVA of 20/70 or better) that included 9 predictors: age, gender, systemic disease, type of surgery, time interval to onset, presenting visual acuity, cultured results, pars plana vitrectomy, and antibiotic therapy. A presenting visual acuity of 20/1,000 or better (OR = 7.07; 95% CI 1.15--43.41; p = 0.035), proper antibiotic therapy (OR = 7.44; 95% CI 1.63--33.91; p = 0.01), and phacoemulsification (OR = 16.95; 95% CI 1.04--276.83; p = 0.047) were found to be significantly associated with a good visual outcome (final BCVA of 20/70 or better) in this multivariate analysis ([Table 4](#t4){ref-type="table"}).

Discussion
==========

These analyses determined the occurrence rate of acute-onset endophthalmitis secondary to cataract surgery in Chinese small and medium-scale departments of ophthalmology from 2011 to 2013. The occurrence rate of postoperative endophthalmitis was calculated to be 0.11% in this analysis of 46,185 cataract surgeries. When compared with our previous survey of Chinese top eye centers, which showed an occurrence rate of 0.033%, the occurrence rate found in this survey was over twice as high. Since the top centers only account for 3.1% of the hospitals in China \[statistics reported by the National Bureau of statistics of China (<http://data.stats.gov.cn>)\], the results of the current survey are more representative of the present medical treatment level in most Chinese hospitals. In developed countries, the incidence of postoperative endophthalmitis ranges from 0.012 to 0.076%[@b3][@b4][@b5][@b6][@b7][@b8][@b9], which is far less than in our study. Recently, the European Society of Cataract & Refractive Surgeons (ESCRS) recommended the intracameral injection of 1 mg of cefuroxime at the close of cataract surgery[@b10]. In addition, one Spanish study showed a subsequent drop in endophthalmitis rates of approximately 15-fold (0.59% to 0.039%) after using intracameral cefuroxime (1 mg)[@b11]. A recent U.S. study also stated a dramatic reduction in infection rates (0.31% to 0.014%) after intracameral antibiotics became a standard prophylactic intervention (moxifloxacin or vancomycin was used in those cases of allergy)[@b12]. These findings lend tremendous support to the clinical benefits of intracameral antibiotic injections.

In China, intracameral antibiotic injections are not widely promoted, but this procedure is worth promoting to prevent postoperative endophthalmitis in Chinese small and medium-scale departments of ophthalmology. However, Witkin[@b13] recently reported 11 cases of postoperative hemorrhagic occlusive retinal vasculitis occurring after cataract surgery. These cases were suspected to be caused by a delayed immune reaction after the use of prophylactic intracameral vancomycin. Considering Witkin's concerns, vancomycin is not recommended in routine prophylactic intracameral injections during cataract surgery.

In U.S. and European studies, a high concentration (5% or 10%) of PVP-I was suggested to effectively lower the incidence of postoperative endophthalmitis[@b5][@b14][@b15][@b16]. However, in a Japanese study, 0.1--1% PVP-I was found to be more rapidly bactericidal than a full-strength solution (10%)[@b17]. Considering the toxicity of PVP-I to the corneal epithelium and endothelium[@b18][@b19], the Chinese Cataract Society has recommended a low concentration application of PVP-I in the conjunctiva. Here, our results support the suggestion that 0.5% PVP-I could reduce the incidence of postoperative endophthalmitis in a large sample. Due to the increased levels of free iodine in a low concentration solution[@b18], irrigation with a 0.5% PVP-I solution in the conjunctiva was beneficial for endophthalmitis prophylaxis. Moreover, a low concentration of PVP-I was found to be effective and safe for the preparation of the conjunctival sac[@b20][@b21]. It seems that a low concentration PVP-I irrigation is a simple and low-cost measure which is worth promoting; however, further randomized controlled trials need to be performed to evaluate the optimum concentration.

A hospital volume of less than 500 cataract surgeries per year was a significant risk factor that we identified for postoperative endophthalmitis (OR = 2.21). At some point, the small-scale departments may have had outdated equipment or surgery rooms. In other words, it is more important to promote the prophylaxis standards in small-scale departments of ophthalmology.

Previous research has shown an increased incidence of endophthalmitis following cataract surgery with clear corneal incisions, when compared with scleral tunnel incisions, due to the instability of the surgical wound[@b22]. Confusingly, recent studies have proposed that the incidence of postoperative endophthalmitis was not related to the incision location[@b7][@b23]. Here, in our study, we observed no relationship between the type of incision and the development of endophthalmitis (p = 0.718). We suggest that a watertight incision might be more important than the type of the incision.

This study has also put the medical levels in China into focus. We found that the ECCE surgery rate was much higher in the small and medium-scale departments when compared with the top eye centers in China (10.3% vs 2.2%)[@b2]. The low coverage of phacoemulsification suggests an imbalance of medical resources in China, including the lesser skills of the surgeons and the lack of proper equipment in most Chinese hospitals. In order to reduce the gaps between hospitals of different levels, financial investments will have to be increased to improve the equipment available in low-level hospitals.

Both the 2013 ESCRS guidelines and the 2010 Chinese National Standard have recommended that broad-spectrum topical, intravitreal, and intravenous antibiotics (e.g., a combination of ceftazidime and vancomycin) be used to treat postoperative endophthalmitis before culture results are available[@b4]. However, we found that more than 40% of the cases did not follow these recommendations. In some patients, only one type of antibiotic (vancomycin or others) was used when a negative culture result was found, and in other cases, the doctors prescribed antibiotics based on their experience, which often did not cover the cultured bacteria. In our study, the rate of culture positivity was low, at only 44.2%. However, it is really dangerous to treat with vancomycin alone in the negative cases, because the gram negative bacteria might be missed. Overall, the final visual outcome of the endophthalmitis cases was generally poor: only 32.7% of the cases had a visual acuities of better than 20/40. Obviously, a nonstandard antibiotic regimen was one of key reasons.

A presenting visual acuity of 20/1,000 or better, proper antibiotic therapy, and phacoemulsification were found to be significantly associated with a good visual outcome. Here, those patients undergoing phacoemulsification had an increased likelihood of having final vision better than 20/70, which was in accordance with Al-Mezaine's report[@b24]. One possible explanation for this finding may be that the initial visual acuity in phacoemulsification is often better than that in the ECCE cases, so the initial visual acuity decrease in the post-phacoemulsification endophthalmitis cases might be more significant than in the post-ECCE endophthalmitis cases. In addition, the presence of a large wound with sutures in the ECCE cases can cause a foreign body sensation that might mask the early symptoms of endophthalmitis. Therefore, the patients with post-phacoemulsification endophthalmitis may recognize the condition sooner and receive more timely treatment.

In summary, the occurrence rate of acute-onset endophthalmitis following cataract surgery was 0.11% in Chinese small and medium-scale departments of ophthalmology, which lags behind the levels of developed countries and Chinese top eye centers. Our findings suggest that intraoperative PCR with vitreous loss and a small hospital volume are major risk factors for developing endophthalmitis, while irrigation with a 0.5% PVP-I solution was an effective prophylaxis against it. Overall, phacoemulsification, better visual acuity at presentation, and proper antibiotic therapy are good predictors of a positive prognosis. Increasing financial investments and continuing education for physicians are expected to improve the level of care provided by most hospitals.

Methods
=======

The study design was a retrospective, consecutive case series. We reviewed patients who underwent standard phacoemulsification or extracapsular cataract extraction (ECCE) with intraocular lens (IOL) implantation in 30 small and medium-scale departments of ophthalmology, between January 1, 2011 and December 31, 2013. We collected all cases with acute-onset endophthalmitis who were diagnosed within 6 weeks of cataract surgery. The small and medium-scale departments of ophthalmology were defined as those with cataract surgery volumes ranging from 10 to 100 cases per month. We randomly sampled 30 departments from each region of China, which were distributed evenly, and located in cities with different economic levels.

Those patients who underwent combined procedures, such as penetrating keratoplasty or trabeculectomy, were not included in our study. In addition, those patients with presumed traumatic endophthalmitis, endogenous endophthalmitis, and delayed-onset endophthalmitis (6 weeks after surgery) were also excluded. This study was conducted under the approval of the Ethical Review Committees of these 30 hospitals, and conformed to the tenets of the Declaration of Helsinki[@b25]. Informed consent was obtained from all of the subjects.

The procedures were performed according to standardized techniques. In the phacoemulsification, a 3-mm superior scleral tunnel incision was made in 7.0%, a limbus tunnel incision was made in 18.8%, and a clear corneal incision was made in 74.2% of the patients. Then, a continuous curvilinear capsulorhexis was performed. After the emulsification of the lens, a foldable IOL was inserted, and the wound was hydrated. With the ECCE, a 9-mm superior scleral tunnel incision was made, a can-opener capsulotomy was performed, and a polymethyl methacrylate (PMMA) IOL was implanted. The wound was then closed with a minimum of 5 interrupted 10--0 nylon sutures.

For the perioperative infection prophylaxis, preoperative topical antibiotics were routinely administered for 1--3 days, while postoperative topical antibiotics (levofloxacin or tobramycin) and steroid eye drops were prescribed for 1--2 weeks. The other prophylaxis procedures differed among the 30 hospitals ([Table 5](#t5){ref-type="table"}). The patients were followed up postoperatively on the first day and at 1 week, 1 month, and 2 months afterwards.

Acute-onset endophthalmitis was clinically diagnosed according to a standardized protocol (ICD-9 code 360.0), and the details were explained in our previous study[@b4]. When a diagnosis of endophthalmitis was made, the patient immediately underwent an aqueous and/or vitreous tap and/or vitrectomy to isolate any organisms. Both culture-positive and culture-negative cases were included, and after sampling the organisms, antibiotic therapy began. A pars plana vitrectomy was applied to the patients who presented with light vision, light perception, or worse[@b26][@b27].

The data collected from the patients included the following: age, gender, systemic disease, inpatient or outpatient status, hospital characteristics (surgery volume, geographic pattern, and general level), infection prophylaxis (e.g., 0.5% povidone iodine for the conjunctiva preparation or not), type of surgery (phacoemulsification or ECCE), location and size of incision, complications during surgery, time to onset of endophthalmitis, visual acuity at presentation, diagnostic procedures performed, culture results, treatment, and follow-up time.

The occurrence rate of acute-onset endophthalmitis following cataract surgery was calculated by each department, based on the first nine factors mentioned above. The 95% CIs for the occurrence rate estimates were calculated assuming a binomial proportion. A multivariate analysis was used to determine whether the factors were independent risk factors for the occurrence of endophthalmitis. A logistic regression model based on the 50 endophthalmitis patients (minus 2 cases with a lack of presenting visual acuity) was used to identify any possible factors associated with achieving a good visual outcome (a final BCVA of 20/70 or better). A p-value of less than 0.05 was considered to be statistically significant, and all of the analyses (except when noted) were performed using the Statistical Package for the Social Sciences (SPSS) version 22.0 (SPSS Inc., Chicago, Illinois, USA).
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###### Occurrence rate of acute-onset postoperative endophthalmitis among different hospitals.

  Hospital    Region   General level of located city   Endophthal-mitis Cases (n)   Effective cataract surgeries (n)   Total cataract surgeries (n)   Occurrence rate per 100 (95% Confidence Interval)
  ---------- -------- ------------------------------- ---------------------------- ---------------------------------- ------------------------------ ---------------------------------------------------
  1             EC                3-tier                           3                              902                              2050                               0.33 (0.00, 0.71)
  2             EC                4-tier                           1                              386                              1021                               0.26 (0.00, 0.77)
  3             EC                4-tier                           1                              710                              1040                               0.14 (0.00, 0.42)
  4             EC                4-tier                           1                              606                              711                                0.17 (0.00, 0.49)
  5             EC                1-tier                           2                              1250                             1610                               0.16 (0.00, 0.38)
  6             EC                1-tier                           1                              2641                             2713                               0.04 (0.00, 0.11)
  7             EC                3-tier                           3                              1458                             3033                               0.21 (0.00, 0.44)
  8             EC                2-tier                           1                              2159                             2503                               0.05 (0.00, 0.14)
  9             EC                4-tier                           1                              761                              1174                               0.13 (0.00, 0.39)
  10            EC                3-tier                           1                              2922                             2932                               0.03 (0.00, 0.10)
  11            SC                3-tier                           6                              3360                             3487                               0.18 (0.04, 0.32)
  12            SC                3-tier                           1                              586                              1348                               0.17 (0.00, 0.50)
  13            SC                4-tier                           1                              3145                             3598                               0.03 (0.00, 0.09)
  14            SC                3-tier                           1                              995                              3195                               0.10 (0.00, 0.30)
  15            NC                1-tier                           2                              3180                             3400                               0.06 (0.00, 0.15)
  16            NC                1-tier                           1                              1880                             1976                               0.05 (0.00, 0.16)
  17            NC                3-tier                           2                              1526                             2014                               0.13 (0.00, 0.31)
  18            NC                3-tier                           1                              2319                             3012                               0.04 (0.00, 0.13)
  19            NC                1-tier                           1                              846                              920                                0.12 (0.00, 0.35)
  20            NC                1-tier                           1                              638                              668                                0.16 (0.00, 0.46)
  21            NC                4-tier                           1                              1648                             2480                               0.06 (0.00, 0.18)
  22            NC                4-tier                           4                              666                              912                                0.60 (0.01, 1.19)
  23            NC                2-tier                           2                              1234                             1371                               0.16 (0.00, 0.39)
  24           MWC                3-tier                           1                              1442                             1847                               0.07 (0.00, 0.21)
  25           MWC                2-tier                           1                              578                              765                                0.17 (0.00, 0.51)
  26           MWC                4-tier                           1                              486                              526                                0.21 (0.00, 0.61)
  27           MWC                3-tier                           6                              1857                             2476                               0.32 (0.06, 0.58)
  28           MWC                4-tier                           1                              1957                             2129                               0.05 (0.00, 0.15)
  29           MWC                3-tier                           1                              3209                             3549                               0.03 (0.00, 0.09)
  30           MWC                4-tier                           2                              838                              932                                0.24 (0.00, 0.57)
  Total        ---                  ---                            52                            46185                            59392                               0.11 (0.08, 0.14)

EC, East China; SC, South China; NC, North China; MWC, Midwest China.

###### Results of Bacterial Cultures in Patients With Endophthalmitis (n = 52).

  Bacterial Cultures/Causative Organisms    Eye (n)   Origin of Specimen  
  ---------------------------------------- --------- -------------------- ----
  Negative bacterial cultures                 29              8            21
  Positive bacterial cultures                 23              7            16
  Gram-positive coagulase-negative            13              5            8
  S. epidermidis                              10              4            6
  S. warneri                                   1              0            1
  S. capitis                                   2              1            1
  Other Gram-positive                          7              2            5
  S. aureus                                    2              0            2
  E. faecalis                                  3              2            1
  P. acnes                                     2              0            2
  Gram-negative                                3              0            3
  P.aeruginosa                                 3              0            3

###### Risk Factor for acute-onset postoperative Endophtalmitis after Cataract Surgery from a Multiple Logistic Regression Model.

  Risk factor                         category      No. of endophthalmitis cases   No. of Effective Cataract Surgeries   Occurrence rate per 100 (95% Confidence Interval)   Multivariate OR (95% Confidence Interval)        p-value        
  ------------------------------- ---------------- ------------------------------ ------------------------------------- --------------------------------------------------- ------------------------------------------- -------------------- -------
  Age                                   \<60                     9                                9624                                  0.094(0.086, 0.101)                                  Reference                         0.889         
                                       60--69                    19                               15122                                 0.126(0.119, 0.133)                              1.34(0.61, 2.97)                                    
                                       70--79                    17                               15773                                 0.108(0.101, 0.114)                              1.15(0.51, 2.59)                                    
                                        ≥80                      7                                5666                                  0.124(0.112, 0.135)                              1.32(0.49, 3.55)                                    
  Gender                                Male                     20                               24316                                 0.082(0.078, 0.087)                                  Reference                         0.199         
                                       Female                    32                               21869                                 0.146(0.140, 0.152)                              1.44(0.82, 2.52)                                    
  hospital                             CSV/Y                   \<500                               17                                          8335                                     0.204(0.193, 0.216)              2.21\*(1.24, 3.94)   0.006
  ≥500                                   35                    37850                       0.093(0.089, 0.096)                               Reference                                                                                       
  Geographic pattern                     EC                      9                                8086                                  0.111(0.117, 0.134)                              1.02(0.45, 2.34)                      0.977         
  SC                                     15                    13795                       0.109(0.102, 0.116)                               Reference                                                                                       
  NC                                     15                    13937                       0.108(0.101, 0.114)                           0.99(0.48, 2.03)                                                                                    
  MWC                                    13                    10367                       0.125(0.117, 0.134)                           1.15(0.55, 2.43)                                                                                    
  General level of located city        1-tier                    8                                10435                                 0.077(0.070, 0.083)                                  Reference                         0.627         
  2-tier                                 4                      3971                       0.101(0.088, 0.113)                           1.31(0.40, 4.37)                                                                                    
  3-tier                                 26                    20576                       0.126(0.120, 0.132)                           1.65(0.75, 3.65)                                                                                    
  4-tier                                 14                    11203                       0.125(0.117, 0.133)                           1.63(0.68, 3.89)                                                                                    
  Type of surgery                      Phaco                     47                               40848                                 0.115(0.111, 0.119)                              0.81(0.32, 2.05)                      0.662         
                                        ECCE                     5                                5337                                  0.094(0.083, 0.104)                                  Reference                                       
  Type of incision                 Clear corneal                 37                               30310                                 0.122(0.117, 0.127)                                  Reference                         0.718         
                                   limber tunnel                 7                                7679                                  0.091(0.083, 0.100)                              0.75(0.33, 1.68)                                    
                                   scleral tunnel                8                                8196                                  0.098(0.089, 0.106)                               0.80(0.37,1.72)                                    
  Place of surgery                   Inpatient                   51                               43326                                 0.118(0.114, 0.122)                                  Reference                         0.201             
                                     Outpatient                  1                                2859                                  0.035(0.026, 0.044)                              0.30(0.04, 2.15)                                        
  0.5% PVP-I                          absence                    25                               16123                                 0.155(0.148, 0.163)                             1.73\*(1.01, 2.98)                     0.046             
                                        use                      27                               30062                                 0.090(0.086, 0.094)                                  Reference                                           
  PCR                                   Yes                      3                                1625                                  0.185(0.160, 0.209)                              1.68(0.52, 5.40)                      0.614             
                                         No                      49                               44560                                 0.110(0.106, 0.114)                                  Reference                                           
  PCR with vitreous loss                Yes                      3                                 623                                  0.482(0.430, 0.533)                             4.40\*(1.34 14.14)                     0.034             
                                         No                      49                               44560                                 0.110(0.106, 0.114)                                  Reference                                           
  PCR without vitreous loss             Yes                      0                                1002                                 0.000 (0.000, 0.000)                                     ---                            0.550             
                                         No                      49                               44560                                 0.110(0.106, 0.114)                                                                                  

PVP-I, povidone iodine; CSV/Y, cataract surgery volume/year; Phaco, phacoemulsification; PCR, posterior capsular rupture.

EC, East China; SC, South China; NC, North China; MWC, Midwest China.

\*Statistically significant P value (\<0.05).

###### Logistic regression analysis of factors associated with achieving a final BCVA of 20/70 or better.

                                       Β Coefficient   p-value   Exp of Β       95% CI
  ----------------------------------- --------------- --------- ---------- ----------------
  Phacoemulsification                      2.830        0.047     16.945    1.037, 276.832
  Presenting visual acuity ≥20/1000        2.007        0.035     7.074     1.153, 43.413
  Proper antibiotics                       1.956        0.01      7.439     1.632, 33.907
  Constant                                −4.345                                   

Exp, exponentiation; CI, Confidence Interval.

###### Infection prophylaxes of 30 hospitals.

  Hospital    Lash trimming   0.5% PVP-I solution application   Antibiotics in irrigating solutions   Subconjunctival antibiotics   Ophthalmic ointment application
  ---------- --------------- --------------------------------- ------------------------------------- ----------------------------- ---------------------------------
  1                 −                       \+                                   −                                 −                        0.3% tobramycin
  2                \+                        −                                   −                                 −                        0.3% tobramycin
  3                \+                       \+                                   −                                 −                        0.3% tobramycin
  4                \+                        −                                   −                                 −                               −
  5                 −                       \+                                   −                                 −                        0.3% tobramycin
  6                 −                       \+                                   −                                 −                        0.3% tobramycin
  7                 −                       \+                                   −                                 −                        0.3% tobramycin
  8                \+                       \+                                   −                                 −                               −
  9                \+                        −                                   −                                 −                        0.3% tobramycin
  10                −                       \+                                   −                                 −                        0.3% tobramycin
  11               \+                        −                          Tobramycin 16 mg/l              Tobramycin 4 mg/0.1 ml              0.3% tobramycin
  12                −                        −                           Getamicin 8 mg/l               Tobramycin 4 mg/0.1 ml              0.3% tobramycin
  13                −                       \+                                   −                                 −                        0.3% tobramycin
  14                −                       \+                                   −                                 −                        0.3% tobramycin
  15                −                        −                                   −                                 −                        0.3% tobramycin
  16               \+                       \+                                   −                      Tobramycin 4 mg/0.1 ml              0.3% tobramycin
  17               \+                        −                                   −                                 −                        0.3% tobramycin
  18               \+                       \+                                   −                                 −                        0.3% tobramycin
  19                −                        −                           Getamicin 8 mg/l                          −                               −
  20                −                       \+                                   −                      Tobramycin 4 mg/0.1 ml                     −
  21               \+                        −                                   −                                 −                               −
  22               \+                        −                                   −                                 −                        0.3% tobramycin
  23                −                        −                                   −                                 −                        0.3% tobramycin
  24                −                       \+                                   −                                 −                        0.3% tobramycin
  25                −                       \+                                   −                                 −                        0.3% tobramycin
  26               \+                        −                                   −                                 −                        0.3% tobramycin
  27                −                       \+                                   −                                 −                        0.3% tobramycin
  28               \+                       \+                                   −                                 −                               −
  29                −                       \+                                   −                                 −                        0.3% tobramycin
  30                −                        −                                   −                                 −                        0.3% tobramycin

PVP-I, povidone-iodine.
